文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

2024年人用西尼罗病毒疫苗会议总结:探究研发障碍

Summary of human West Nile virus vaccine meeting, 2024: Investigating barriers to development.
PubMed 文献 · Vaccine · 2025-11-05

西尼罗病毒(WNV)是蚊媒嗜神经病毒,近25年在美国和欧洲造成显著短期和长期疾病负担与死亡,媒介控制措施基本未能减轻其影响。美国疾病控制与预防中心于2024年4月召集政府、产业、学术界和监管机构会议,识别出五项人用WNV疫苗上市障碍,包括传播间歇性且时空变异大妨碍III期试验、无症状感染率高影响终点、缺乏替代终点、需标准化试剂和检测方法、经济支持不足,并提出后续活动方向。

要点

  • 西尼罗病毒近25年在美国和欧洲造成显著短期和长期疾病负担与死亡,媒介控制基本未能减轻影响。
  • 人用WNV疫苗上市面临五项障碍:传播间歇且时空变异大、无症状感染率高、缺乏替代终点、需标准化试剂和检测方法、经济支持不足。
  • 后续活动包括制定目标产品概况、建立动物模型和替代终点、开发鉴别感染与接种的诊断检测、销售预测分析、探索合作和考虑加速审批途径。

核心结论

  • 需要公共卫生和科学界合作,确保人用疫苗可用来降低西尼罗病毒持续造成的疾病负担和死亡。

研究设计与样本

  • 美国疾病控制与预防中心于2024年4月召集美国联邦和市政府、产业、学术界和监管机构的关键利益相关者召开会议。

主要发现

  • 会议讨论了流行病学、疫情暴发影响、人用疫苗理由、动物模型和保护相关物、诊断考虑、临床开发中的人用候选疫苗和疫苗开发监管考虑。
  • 识别的人用WNV疫苗上市障碍包括:传播呈间歇性且疾病发生的地理和时间变异大妨碍评估疫苗效力的III期临床试验可行性;无症状感染率高影响临床试验终点考虑;缺乏预测临床获益的替代终点;需要标准化试剂和检测方法来定量抗体;疫苗开发和商业生产的经济支持极少。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

West Nile virus (WNV) is a neurotropic mosquito-borne virus that re-emerged in the last 25 years to cause substantial short- and long-term morbidity and mortality, particularly in the United States and Europe. Attempts to mitigate the impact of WNV by vector control have been largely unsuccessful. A WNV vaccine could be effective in decreasing disease burden. To identify and address important barriers to licensing human WNV vaccines, U.S. Centers for Disease Control and Prevention convened a meeting of key stakeholders from the U.S. federal and municipal governments, industry, academia, and regulatory agencies in April 2024. Topics discussed included epidemiology, impact of outbreaks, rationale for human vaccines, animal models and correlates of protection, diagnostic considerations, candidate human vaccines in clinical development, and regulatory considerations for vaccine development. Several barriers to human WNV vaccine licensure were identified, including 1) episodic transmission with substantial geographic and temporal variability in disease occurrence impeding the feasibility of phase III clinical trials evaluating vaccine efficacy against WNV disease, 2) high asymptomatic attack rate affecting potential clinical trial endpoint considerations, 3) lack of a surrogate endpoint to predict clinical benefit, 4) need for standardized reagents and assays to quantitate antibodies, and 5) minimal economic support for vaccine development and commercial manufacturing. Future activities to support advancing WNV vaccine development and licensure involve developing a target product profile, establishing suitable animal models and surrogate endpoints to predict clinical benefit, developing a diagnostic test to differentiate immunologic response to infection versus vaccination, conducting a sales forecast analysis, exploring partnerships that could advance vaccine development and licensure, and considering alternative approaches for licensure such as the accelerated approval pathway. We need to work collaboratively as a public health and scientific community to ensure human vaccines are available to decrease the ongoing morbidity and mortality caused by WNV.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Nett RJ, Brault AC, Lambert AJ, et al. Summary of human West Nile virus vaccine meeting, 2024: Investigating barriers to development. Vaccine. 2025. PMID: 41197444. doi:10.1016/j.vaccine.2025.127938

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。